Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F
Cancers (Basel). 2025; 17(2).
PMID: 39858092
PMC: 11763395.
DOI: 10.3390/cancers17020310.
Limbach M, Kuehl R, Koeppel M, Dreger P, Luft T, Bohus M
Support Care Cancer. 2025; 33(2):89.
PMID: 39794666
PMC: 11723852.
DOI: 10.1007/s00520-024-09140-8.
Solis-Armenta R, Rodriguez-Rodriguez S, Hernandez-Perez A, Paulina-Zapata N, Delgado N, Montano-Figueroa E
Ann Hematol. 2024; 103(10):4089-4097.
PMID: 39177797
DOI: 10.1007/s00277-024-05956-w.
Robinson C, Habib A, Klomjit N, Cao Q, Holtan S
Front Transplant. 2024; 3:1352413.
PMID: 38993762
PMC: 11235361.
DOI: 10.3389/frtra.2024.1352413.
Pidala J, Carpenter P, Onstad L, Pavletic S, Hamilton B, Chen G
PLoS One. 2024; 19(5):e0298026.
PMID: 38753616
PMC: 11098321.
DOI: 10.1371/journal.pone.0298026.
Modified Delphi panel consensus recommendations for management of severe aplastic anemia.
Babushok D, DeZern A, de Castro C, Rogers Z, Beenhouwer D, Broder M
Blood Adv. 2024; 8(15):3946-3960.
PMID: 38669341
PMC: 11331724.
DOI: 10.1182/bloodadvances.2023011642.
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D
Blood. 2024; 143(26):2722-2734.
PMID: 38635762
PMC: 11251200.
DOI: 10.1182/blood.2023023447.
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard J
Bone Marrow Transplant. 2023; 59(2):232-238.
PMID: 38007531
DOI: 10.1038/s41409-023-02147-5.
Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.
Bhatt V, Wichman C, Koll T, Fisher A, Wildes T, Berger A
J Geriatr Oncol. 2023; 15(1):101676.
PMID: 38000343
PMC: 11101205.
DOI: 10.1016/j.jgo.2023.101676.
Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation.
Salhotra A, Yuan S, Ali H
Front Oncol. 2023; 13:1196564.
PMID: 37700828
PMC: 10493308.
DOI: 10.3389/fonc.2023.1196564.
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation.
Elias S, Brown S, Devlin S, Barker J, Cho C, Chung D
Br J Haematol. 2023; 203(5):840-851.
PMID: 37614192
PMC: 10843799.
DOI: 10.1111/bjh.19055.
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials.
Silbert S, Madan S, Holland E, Steinberg S, Little L, Foley T
Blood Adv. 2023; 7(18):5566-5578.
PMID: 37486616
PMC: 10514106.
DOI: 10.1182/bloodadvances.2023009789.
Rationale for the evaluation of renal functional reserve in allogeneic stem cell transplantation candidates: a pilot study.
Mancianti N, Guarnieri A, Lenoci M, Toraldo F, Salvo D, Belluardo M
Clin Kidney J. 2023; 16(6):996-1004.
PMID: 37261004
PMC: 10229270.
DOI: 10.1093/ckj/sfac268.
Characteristics of Distress and Support Group Participation in Caregivers of Older Allogeneic Hematopoietic Cell Transplantation Patients: A Single Institution Retrospective Review.
Elko T, Brown S, Lobaugh S, Devlin S, Jakubowski A, Perales M
J Adv Pract Oncol. 2023; 14(2):127-137.
PMID: 37009407
PMC: 10062532.
DOI: 10.6004/jadpro.2023.14.2.3.
Clinical trial participation predicts improved survival in older adults receiving allogeneic blood and marrow transplant.
Thornton C, Bandeen-Roche K, Dolinar M, Roberts Lavigne L, Lansey D, Jones R
BMC Geriatr. 2023; 23(1):120.
PMID: 36869287
PMC: 9985233.
DOI: 10.1186/s12877-023-03803-7.
The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators.
Sorror M
Blood. 2023; 141(18):2173-2186.
PMID: 36800564
PMC: 10273168.
DOI: 10.1182/blood.2022017999.
Nutritional support in allogeneic hematopoietic stem cell transplantation Asian perspective.
Fuji S, Cheng J, Yakushijin K, Wanitpongpun C
Blood Cell Ther. 2023; 5(2):54-60.
PMID: 36710949
PMC: 9870687.
DOI: 10.31547/bct-2021-024.
Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia.
Fingrut W, Gyurkocza B, Flynn J, Davis E, Devlin S, Scaradavou A
Blood Adv. 2022; 7(15):3824-3833.
PMID: 36240477
PMC: 10393759.
DOI: 10.1182/bloodadvances.2022008572.
Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation.
Schierbeck F, Mortensen J, Andersen N, Friis L, Kornblit B, Petersen S
Eur J Haematol. 2022; 110(1):50-59.
PMID: 36153797
PMC: 10092052.
DOI: 10.1111/ejh.13869.
Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies.
Bi X, Gergis U, Wagner J, Carabasi M, Filicko-OHara J, Ohara W
Bone Marrow Transplant. 2022; 57(11):1671-1680.
PMID: 35986105
PMC: 9388981.
DOI: 10.1038/s41409-022-01780-w.